Validation of Revised Chinese Version of PD-CRS in Parkinson’s Disease Patients

Table 1

Demographic and clinical characteristics between PD-NC, PD-MCI, and PDD groups.

	PD-NC	PD-MCI	PDD
N	37	44	11	—
Age	68.08 ± 6.202	69.82 ± 6.366	71.27 ± 4.563	0.237^a
Male (%)	25 (67.6%)	34 (77.3%)	7 (63.6%)	0.511^b
Education (year)	12.35 ± 2.879	11.63 ± 3.441	10.73 ± 2.284	0.225^c
Disease duration (year)	5.32 ± 5.716	5.18 ± 3.598	7.82 ± 3.401	0.033^c
H–Y staging	1.70 ± 0.6714	1.90 ± 0.6522	2.45 ± 0.650	0.009^c
Smoke (−)	34 (91.9%)	38 (86.4%)	10 (90.9%)	0.712^b
Alcohol (−)	34 (91.9%)	39 (88.6%)	9 (81.8%)	0.656^b
Diabetes (−)	32 (86.5%)	39 (88.6%)	9 (81.8%)	0.838^b
Hypertension (−)	27 (73.0%)	29 (65.9%)	7 (63.6%)	0.739^b
Coronary heart disease (−)	31 (83.8%)	36 (81.8%)	11 (100%)	0.139^b
Cerebrovascular disease (−)	33 (89.2%)	39 (88.6%)	10 (90.0%)	0.976^b
Levodopa (+)	25 (67.6%)	36% (81.8%)	10 (90.0%)	0.151^b
Dopamine agonists (+)	22 (59.5%)	20 (45.5%)	5 (45.5%)	0.418^b
COMT inhibitor (+)	3 (8.1%)	10 (22.7%)	0 (0%)	0.061^b
MAO-B inhibitor (+)	13 (35.1%)	8 (18.2%)	1 (9.1%)	0.090^b
Anticholinergic (+)	0 (0%)	2 (4.5%)	1 (9.1%)	0.177^b
Amantadine (+)	3 (8.1%)	7 (15.9%)	2 (18.2%)	0.488^b
LEDD (mg/d)	323.97 ± 249.571	430.73 ± 287.325	540.91 ± 301.719	0.038^a
UPDRS-III	12.89 ± 8.906	20.48 ± 13.473	26.00 ± 11.773	0.001^c
BDI	5.68 ± 4.295	11.45 ± 8.019	16.45 ± 10.727	<0.001^c
MDRS	138.16 ± 6.265	131.43 ± 9.260	114.27 ± 15.755	<0.001^c

^aOne-way analysis of variance (ANOVA); ^bChi-square test; ^cKruskal–Wallis test. PD: Parkinson’s disease; PD-NC: PD patients with normal cognition; PD-MCI: PD patients with mild cognitive impairment; PDD: PD patients with dementia; H–Y staging: Hoehn and Yahr staging; COMT inhibitor: catechol O-methyltransferase inhibitor; MAO-B inhibitor: monoamine oxidase-B inhibitor; LEDD: levodopa equivalent daily dose; UPDRS-III: the Unified Parkinson’s Disease Rating Scale part III; BDI: Beck Depression Inventory; MDRS: Mattis Dementia Rating Scale.